Granted Patent
B2
US 12,421,506 · App. 17/123,918 · Granted Sep 23, 2025
Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
Assignees:
THE BROAD INSTITUTE, INC.; MASSACHUSETTS INSTITUTE OF TECHNOLOGY; PRESIDENT AND FELLOWS OF HARVARD COLLEGE
C12N9/22C12N15/113C12N15/115C12N15/63C12N15/907C12Y301/00C12N2310/10C12N2310/16C12N2310/20C12N2310/3519
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The invention provides for systems, methods, and compositions for altering expression of target gene sequences and related gene products. Provided are structural information on the Cas protein of the CRISPR-Cas system, use of this information in generating modified components of the CRISPR complex, vectors and vector systems which encode one or more components or modified components of a CRISPR complex, as well as methods for the design and use of such vectors and components. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for utilizing the CRISPR-Cas system. In particular the present invention comprehends optimized functional CRISPR-Cas enzyme systems. In particular the present invention comprehends engineered new guide architectures to be used in optimized CRISPR-Cas enzyme systems.
Claims (24)
1. A chimeric single guide RNA molecule (sgRNA), comprising:
(i) a guide sequence capable of hybridizing to a target sequence in a genomic locus of interest in a eukaryotic cell, wherein the guide sequence has a length of 21 to 23 nucleotides and comprises a 5′-terminal guanosine (G) residue,
(ii) a tracr sequence, and
(iii) a tracr-mate sequence capable of hybridizing with the tracr sequence,
wherein the sgRNA is capable of forming a CRISPR-Cas complex with Staphylococcus aureus Cas9 (SaCas9).
2. The sgRNA of claim 1 , wherein a poly U tract in wild-type tracr-mate sequence, which is located at positions 2-5 starting from 3′-end of the guide sequence, is replaced with poly C.
3. The sgRNA of claim 2 , wherein a poly A tract in wild-type tracr sequence, which basepairs with the poly U tract in wild-type tracr-mate sequence, is replaced with poly G.
4. The sgRNA of claim 1 , wherein the guide sequence has a length of 21 nucleotides.
5. The sgRNA of claim 1 , wherein the guide sequence has a length of 22 nucleotides.
6. The sgRNA of claim 1 , wherein the guide sequence has a length of 23 nucleotides.
7. The sgRNA of claim 1 , wherein a repeat:anti-repeat duplex formed by hybridization of the tracr-mate sequence and the tracr sequence is truncated compared to that of a wild-type Staphylococcus aureus CRISPR-Cas9 system.
8. The sgRNA of claim 7 , wherein the tracr-mate sequence has a length of 14-25 nucleotides.
9. The sgRNA of claim 1 , wherein the tracr sequence has a length of 50-100 nucleotides.
10. The sgRNA of claim 1 , wherein the sgRNA comprises at least one loop that comprises an insertion of an RNA sequence capable of binding to an adaptor protein.
11. The sgRNA of claim 10 , wherein the inserted RNA sequence is an aptamer.
12. A composition comprising the sgRNA of claim 11 bound to an adaptor protein.
13. The composition of claim 12 , wherein the adaptor protein is linked to a heterologous functional domain, optionally wherein the heterologous functional domain is a transcriptional activation domain or a transcriptional repressor domain.
14. A composition comprising a CRISPR-Cas complex, wherein the CRISPR-Cas complex comprises the sgRNA of claim 1 and a SaCas9 protein.
15. The composition of claim 14 , wherein the SaCas9 protein is linked to a heterologous functional domain, optionally wherein the heterologous functional domain is a transcriptional activation domain or a transcriptional repressor domain.
16. A polynucleotide encoding the sgRNA of claim 1 .
17. A vector comprising the polynucleotide of claim 16 operably linked to a promoter.
18. The vector of claim 17 , further comprising a polynucleotide encoding a SaCas9 protein.
19. A eukaryotic cell transformed with the vector of claim 17 .
20. A eukaryotic cell comprising the sgRNA of claim 1 .
Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 12, 2025
From: ZHANG, FENG
To: THE BROAD INSTITUTE, INC.; MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 071089/0553 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 12, 2025
From: RAN, FEI
To: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Reel/Frame 071275/0854 →
LICENSE
Recorded Apr 1, 2025
From: BROAD INSTITUTE, INC.
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 070703/0829 →
Continuity (5)
Continuation In Part
PCTUS2014070152
· Dec 12, 2014
Provisional Application
61939256
· Feb 12, 2014
Provisional Application
61915267
· Dec 12, 2013
References Cited (400)
US 5622856A
· Natsoulis
· 1997
[cited by applicant]
US 6251677B1
· Wilson et al.
· 2001
[cited by applicant]
US 7601492B2
· Fu et al.
· 2009
[cited by applicant]
US 7691995B2
· Zamore et al.
· 2010
[cited by applicant]
US 8697359B1
· Zhang
· 2014
[cited by applicant]
US 8771945B1
· Zhang
· 2014
[cited by applicant]
US 8865406B2
· Zhang et al.
· 2014
[cited by applicant]
US 8871445B2
· Cong et al.
· 2014
[cited by applicant]
US 8889418B2
· Zhang et al.
· 2014
[cited by applicant]
US 8895308B1
· Zhang et al.
· 2014
[cited by applicant]
US 8932814B2
· Cong et al.
· 2015
[cited by applicant]
US 8945839B2
· Zhang
· 2015
[cited by applicant]
US 8993233B2
· Zhang et al.
· 2015
[cited by applicant]
US 9512446B1
· Joung et al.
· 2016
[cited by applicant]
US 9549901B2
· Shi et al.
· 2017
[cited by applicant]
US 9597357B2
· Gregory et al.
· 2017
[cited by applicant]
US 9623071B2
· Guo et al.
· 2017
[cited by applicant]
US 9637739B2
· Siksnys et al.
· 2017
[cited by applicant]
US 9701964B2
· Clube et al.
· 2017
[cited by applicant]
US 9738908B2
· Wu
· 2017
[cited by applicant]
US 9834791B2
· Zhang et al.
· 2017
[cited by applicant]
US 9873894B2
· Conway et al.
· 2018
[cited by applicant]
US 9926546B2
· Joung et al.
· 2018
[cited by applicant]
US 20030186238A1
· Allawi et al.
· 2003
[cited by applicant]
US 20040111221A1
· Beattie et al.
· 2004
[cited by applicant]
US 20050196851A1
· Uckun
· 2005
[cited by applicant]
US 20050220796A1
· Dynan et al.
· 2005
[cited by applicant]
US 20060171924A1
· Luo et al.
· 2006
[cited by applicant]
US 20060178297A1
· Troy et al.
· 2006
[cited by applicant]
US 20070244031A1
· Lu et al.
· 2007
[cited by applicant]
US 20100076057A1
· Sontheimer et al.
· 2010
[cited by applicant]
US 20100081707A1
· Ali et al.
· 2010
[cited by applicant]
US 20110016540A1
· Weinstein et al.
· 2011
[cited by applicant]
US 20110239315A1
· Bonas et al.
· 2011
[cited by applicant]
US 20140315985A1
· May et al.
· 2014
[cited by applicant]
US 20140342456A1
· Mali et al.
· 2014
[cited by applicant]
US 20140356956A1
· Church et al.
· 2014
[cited by applicant]
US 20140357530A1
· Zhang et al.
· 2014
[cited by applicant]
US 20150247150A1
· Zhang et al.
· 2015
[cited by applicant]
US 20150291965A1
· Zhang et al.
· 2015
[cited by applicant]
US 20160017366A1
· Chen et al.
· 2016
[cited by applicant]
US 20160281072A1
· Zhang
· 2016
[cited by applicant]
US 20160298137A1
· Chen et al.
· 2016
[cited by applicant]
US 20160340662A1
· Zhang et al.
· 2016
[cited by applicant]
US 20170175144A1
· Zhang et al.
· 2017
[cited by applicant]
US 20170191082A1
· Chen et al.
· 2017
[cited by applicant]
US 20180230495A1
· Doudna et al.
· 2018
[cited by applicant]
BR 112015013784
· 2017
[cited by applicant]
CA 2619833A1
· 2007
[cited by applicant]
CN 101228176
· 2008
[cited by applicant]
CN 103343120
· 2013
[cited by applicant]
CN 103388006
· 2013
[cited by applicant]
CN 103668472
· 2014
[cited by applicant]
CN 104520429A
· 2015
[cited by applicant]
CN 104854241A
· 2015
[cited by applicant]
CN 107532161A
· 2018
[cited by applicant]
EP 2591770A2
· 2013
[cited by applicant]
EP 2784162
· 2014
[cited by applicant]
EP 2764103
· 2014
[cited by applicant]
EP 2771468
· 2014
[cited by applicant]
EP 2828386A1
· 2015
[cited by applicant]
FR 2872170A1
· 2005
[cited by applicant]
IN 492015
· 2015
[cited by applicant]
JP 2004519245A
· 2004
[cited by applicant]
JP 2004537285A
· 2004
[cited by applicant]
JP 2005509409A
· 2005
[cited by applicant]
JP 2006513694A
· 2006
[cited by applicant]
JP 2006518996A
· 2006
[cited by applicant]
JP 2007501626A
· 2007
[cited by applicant]
JP 2009502170A
· 2009
[cited by applicant]
JP 2009536827A
· 2009
[cited by applicant]
JP 2010507680A
· 2010
[cited by applicant]
JP 2010522547A
· 2010
[cited by applicant]
JP 2012506254A
· 2012
[cited by applicant]
JP 2012508235
· 2012
[cited by applicant]
JP 2012510812A
· 2012
[cited by applicant]
JP 2012511332A
· 2012
[cited by applicant]
JP 2012523234A
· 2012
[cited by applicant]
JP 2012529287A
· 2012
[cited by applicant]
JP 2013500045A
· 2013
[cited by applicant]
JP 2013513389A
· 2013
[cited by applicant]
JP 2013518602A
· 2013
[cited by applicant]
JP 2013544077A
· 2013
[cited by applicant]
JP 2014526279A
· 2014
[cited by applicant]
JP 2015523856A
· 2015
[cited by applicant]
JP 2016500003A
· 2016
[cited by applicant]
JP 2016500262A
· 2016
[cited by applicant]
JP 2016501531
· 2016
[cited by applicant]
JP 2016501532A
· 2016
[cited by applicant]
JP 2016025710A
· 2016
[cited by applicant]
JP 2016502840A
· 2016
[cited by applicant]
JP 2016504026A
· 2016
[cited by applicant]
JP 2016505256A
· 2016
[cited by applicant]
JP 2016093196
· 2016
[cited by applicant]
JP 2016516169A
· 2016
[cited by applicant]
JP 2016517954A
· 2016
[cited by applicant]
JP 2016131404A
· 2016
[cited by applicant]
JP 2016520317A
· 2016
[cited by applicant]
JP 2016521554A
· 2016
[cited by applicant]
JP 2016521975A
· 2016
[cited by applicant]
JP 2016521995
· 2016
[cited by applicant]
JP 2016523082A
· 2016
[cited by applicant]
JP 2016524472
· 2016
[cited by applicant]
JP 2016182140A
· 2016
[cited by applicant]
JP 2017501151A
· 2017
[cited by applicant]
JP 2017501699
· 2017
[cited by applicant]
JP 6395765
· 2018
[cited by applicant]
RU 2009136452A
· 2011
[cited by applicant]
WO WO02074968A1
· 2002
[cited by applicant]
WO WO02080851A2
· 2002
[cited by applicant]
WO WO03014318A2
· 2003
[cited by applicant]
WO WO03104414A2
· 2003
[cited by applicant]
WO WO2004029219A2
· 2004
[cited by applicant]
WO WO2004046321A2
· 2004
[cited by applicant]
WO WO2004062618A2
· 2004
[cited by applicant]
WO WO2005014791
· 2005
[cited by applicant]
WO WO2005049642A2
· 2005
[cited by applicant]
WO WO2007014275A2
· 2007
[cited by applicant]
WO WO2007134161A2
· 2007
[cited by applicant]
WO WO2008093152A1
· 2008
[cited by applicant]
WO WO2008108989
· 2008
[cited by applicant]
WO WO2008116860A2
· 2008
[cited by applicant]
WO WO2008147438A2
· 2008
[cited by applicant]
WO WO2010011961A2
· 2010
[cited by applicant]
WO WO2010048228A2
· 2010
[cited by applicant]
WO WO2010054108
· 2010
[cited by applicant]
WO WO2010065123A1
· 2010
[cited by applicant]
WO WO2010068816A1
· 2010
[cited by applicant]
WO WO2010075424A2
· 2010
[cited by applicant]
WO WO2010079430A1
· 2010
[cited by applicant]
WO WO2010118077A1
· 2010
[cited by applicant]
WO WO2010143917
· 2010
[cited by applicant]
WO WO2011011767A1
· 2011
[cited by applicant]
WO WO2011016840A2
· 2011
[cited by applicant]
WO WO2011036510A1
· 2011
[cited by applicant]
WO WO2011064736A1
· 2011
[cited by applicant]
WO WO2011072246A2
· 2011
[cited by applicant]
WO WO2011076873A1
· 2011
[cited by applicant]
WO WO2011100058
· 2011
[cited by applicant]
WO WO2011146121A1
· 2011
[cited by applicant]
WO WO2012012738A1
· 2012
[cited by applicant]
WO WO2012031205
· 2012
[cited by applicant]
WO WO2012051343A1
· 2012
[cited by applicant]
WO WO2012149470A1
· 2012
[cited by applicant]
WO WO2012164565A1
· 2012
[cited by applicant]
WO WO2013044008A2
· 2013
[cited by applicant]
WO WO2013052681
· 2013
[cited by applicant]
WO WO20135052681A1
· 2013
[cited by applicant]
WO WO2013071440A1
· 2013
[cited by applicant]
WO WO2013078400A1
· 2013
[cited by applicant]
WO WO2013082519A2
· 2013
[cited by applicant]
WO WO2013098244
· 2013
[cited by applicant]
WO WO2013130824A1
· 2013
[cited by applicant]
WO WO2013141680A1
· 2013
[cited by applicant]
WO WO2013142578A1
· 2013
[cited by applicant]
WO WO2013155572
· 2013
[cited by applicant]
WO WO2013176772A1
· 2013
[cited by applicant]
WO WO2014165349A1
· 2014
[cited by applicant]
WO WO2014065596A1
· 2014
[cited by applicant]
WO WO2014089290A1
· 2014
[cited by applicant]
WO WO2014093479
· 2014
[cited by applicant]
WO WO2014093595
· 2014
[cited by applicant]
WO WO2014093622A2
· 2014
[cited by applicant]
WO WO2014093635A1
· 2014
[cited by applicant]
WO WO2014093655
· 2014
[cited by applicant]
WO WO2014093661
· 2014
[cited by applicant]
WO WO2014093694A1
· 2014
[cited by applicant]
WO WO2014093701A1
· 2014
[cited by applicant]
WO WO2014093709
· 2014
[cited by applicant]
WO WO2014093712A1
· 2014
[cited by applicant]
WO WO2014093718
· 2014
[cited by applicant]
WO WO2014099744
· 2014
[cited by applicant]
WO WO2014099750A2
· 2014
[cited by applicant]
WO WO2015031775
· 2014
[cited by applicant]
WO WO2014144761A2
· 2014
[cited by applicant]
WO WO2014165825A2
· 2014
[cited by applicant]
WO WO2014186585A2
· 2014
[cited by applicant]
WO WO2014191518A1
· 2014
[cited by applicant]
WO WO2014197568A2
· 2014
[cited by applicant]
WO WO2014197748A2
· 2014
[cited by applicant]
WO WO2014204724A1
· 2014
[cited by applicant]
WO WO2014204725
· 2014
[cited by applicant]
WO WO2014204726A1
· 2014
[cited by applicant]
WO WO2014204727A1
· 2014
[cited by applicant]
WO WO2014204728
· 2014
[cited by applicant]
WO WO2014204729A1
· 2014
[cited by applicant]
WO WO2015006747A2
· 2015
[cited by applicant]
WO WO2015035136A2
· 2015
[cited by applicant]
WO WO2015048577
· 2015
[cited by applicant]
WO WO2015048690A1
· 2015
[cited by applicant]
WO WO2015065964A1
· 2015
[cited by applicant]
WO WO2015070083A1
· 2015
[cited by applicant]
WO WO2015071474A2
· 2015
[cited by applicant]
WO WO2015089351A1
· 2015
[cited by applicant]
WO WO2015089364A1
· 2015
[cited by applicant]
WO WO2015089419A2
· 2015
[cited by applicant]
WO WO2015089427A1
· 2015
[cited by applicant]
WO WO2015113063A1
· 2015
[cited by applicant]
WO WO2016022866A1
· 2016
[cited by applicant]
WO WO2016073955A2
· 2016
[cited by applicant]
WO WO2016141224A1
· 2016
[cited by applicant]
“Crispr Genome Engineering Resources” XP055167591, Oct. 5, 2013, https://web.archive.org/web/2013100500 [retrieved on Feb. 5, 2015].
[cited by applicant]
“Fixes, extra genomes, and improvements to the CRISPR Design Tool” Google Groups, XP055167583, Oct. 21, 2013, URL:https://groups.google.com/forum/#!topic/crispr/g9Q8U1tNSis [retrieved on Feb. 5, 2015].
[cited by applicant]
“The CRISPR Revolution,” Catalyst Magazine, College of Chemistry, University of California, Berkeley, http://catalyst.berkeley.edu/slideshow/the-crispr-revolution/[Dec. 19, 2014 12:40:53] (Jul. 9, 2014).
[cited by applicant]
A. Amsterdam et al., “Identification of 315 genes essential for early zebrafish development,” proc Natl Acad Sci., vol. 101, Aug. 31, 2004, pp. 12792-12797, 6 pages.
[cited by applicant]
A. Fire et al., “Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans,” Nature, vol. 391, Feb. 19, 1998, pp. 806-811, 6 pages.
[cited by applicant]
A. Subramanian et al., “Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles,” Proc Natl Acad Sci., vol. 102, Oct. 25, 2005, pp. 15545-15550, 6 pages.
[cited by applicant]
A.C. Spradling et al., “The Berkeley
[cited by applicant]
A.H. Tong et al., “Global mapping of the yeast genetic interaction network,” Science, vol. 303, Feb. 6, 2004, pp. 808-813, 6 pages.
[cited by applicant]
A.L. Lin and D.H Gutmann, “Advances in the treatment of neurofibromatosis-associated tumours,” Nature, vol. 10, Nov. 2013, pp. 616-624, 9 pages.
[cited by applicant]
A.P. Blanchard and L. Hood, “Sequence to array: probing the genome's secrets,” Nat Biotechnol, vol. 14, Dec. 14, 1996, p. 1649.
[cited by applicant]
Abudayyeh, et al., “C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector,” Science, vol. 10, Jun. 2, 2016, pp. 1-16, 18 pages.
[cited by applicant]
Addgene Materials, “CRISPR/cas Plasmids and Resources”, downloaded from https://www.addgene.org/crispr/, May 6, 2015, 3 pages.
[cited by applicant]
Addgene Materials, “Engineering with Addgene's Help”, Addgene Newsletter, Mar. 2013, downloaded from https://archive.constantcontact.com/fs126/1103481513180/archive/1112756362265.html, Oct. 14, 2014, 4 pages.
[cited by applicant]
Addgene Reagent distribution list for Zhang Lab with Plasmid Name, date unknown (prior to May 10, 2015), 2 pages.
[cited by applicant]
Addgene, “gRNA_Cloning Vector”, retrieved on Jan. 30, 2019, <https://www/addgenen.org/41824/> 2 pages.
[cited by applicant]
Al-Attar, et al., “Clustered regularly interspaced short palindromic repeats (CRISPRs): the hallmark of an ingenious antiviral defense mechanism in prokaryotes” Biol Chem., vol. 392, No. 4, Apr. 2011, pp. 277-289, 13 pa…
[cited by applicant]
Alberts, et al., “Intracellular Compartments and Protein Sorting,” Garland Science, 4 ed., 2002, pp. 671-676, 8 pages.
[cited by applicant]
Allen, et al., “Liposomal drug delivery systems: From concept to clinical applications” Advanced Drug Delivery Reviews, vol. 65, 2013, pp. 36-48, 13 pages.
[cited by applicant]
Andreas, et al., “Enhanced efficiency through nuclear localization signal fusion on phage C31-integrase: activity comparison with Cre and FLPe recombinase in mammalian cells”, Nucleic Acids Research, Apr. 15, 2002, vol.…
[cited by applicant]
[cited by applicant]
Asuri, P., et al., “Directed Evolution of Adeno-Associated Virus for Enhanced Gene Delivery and Gene Targeting in Human Pluripotent Stem Cells,” Molecular Therapy, vol. 30, 2012, No. pp. 329-338, 10 pages.
[cited by applicant]
Au, et al., “Characterization of a baculovirus nuclear localization signal domain in the late express factor 3 protein”, Virology, vol. 385, 2009, pp. 209-217.
[cited by applicant]
Ausubel, et al. “Compendium of Methods from Current Protocols in Molecular Biology”, Short Protocols in Molecular Biology, 4 ed., 1999, 9-0, 9-4, 5 pages.
[cited by applicant]
Autofluorescence MIT Flow Cytometry Core Facility (2018), 6 pages.
[cited by applicant]
B. Langmead et al., “Ultrafast and memory-efficient alignment of short DNA sequences to the human genome,” Genome biology, vol. 10, Mar. 4, 2009, 10 pages.
[cited by applicant]
B.Langmead and S.L. Salzberg, “Fast gapped-read alignment with Bowtie 2,” Nat Meth, vol. 9, 2012, pp. 357-359, 3 pages.
[cited by applicant]
B.Scappini et al., “Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein,” Cancer, vol. 100, Apr. 1, 2004, pp. 1459-1471, 13 pages.
[cited by applicant]
B.Sonnichsen et al., “Full-genome RNAi profiling of early embryogenesis in Caenorhabditis elegans,” Nature, vol. 434, Mar. 24, 2005, pp. 462-469, 8 pages.
[cited by applicant]
Bae, T. and Schneewind, O. “Allelic replacement in
[cited by applicant]
Baena-Lopez, L., et al., “Accelerated homologous recombination and subsequent genome modification in
[cited by applicant]
Baiker, et al. “The Immediate-Early 63 Protein of Varicella-Zoster Virus: Analysis of Functional Domains Required for Replication In Vitro and for T-Cell and Skin Tropism in the SCIDhu Model In Vivo”, Journal of Virolog…
[cited by applicant]
Baker, M., “Gene editing at CRISPR Speed,” Nature Biotechnology, vol. 32, 2014, pp. 309-312, 4 pages.
[cited by applicant]
Balboa, et al., “Conditionally Stabilized dCas9 Activator for Controlling Gene Expression in Human Cell Reprogramming and Differentiation. (plus Supplemental Information)”, Stem Cell Reports, vol. 5, Sep. 8, 2015, pp. 4…
[cited by applicant]
Banaszewska, A., et al., “Proprotein Convertase Subtilisin/Kexin Type 9: A New Target Molecule For Gene Therapy,” Cellular & Molecular Biology Letters, vol. 17, 2012, pp. 228-239, 12 pages.
[cited by applicant]
Barrangou and Van Der Oost (Eds.), “CRISPR-Cas Systems,” Springer Heidelberg, 2013, pp. i-299.
[cited by applicant]
Barrangou, R. et al., “CRISPR provides acquired resistance against viruses in prokaryotes,” Science, vol. 315, Mar. 23, 2007, pp. 1709-1712, 6 pages.
[cited by applicant]
Barrangou, R., “RNA-mediated programmable DNA cleavage,” Nature Biotechnology, vol. 30, 2012, pp. 836-388, 13 pages.
[cited by applicant]
Bassett, et al. “Highly Efficient Targeted Mutagenesis of
[cited by applicant]
Bassett, et al., “A Genome-Wide CRISPR Library for High-Throughput Genetic Screening in Drosophila Cells,” Journal of Genetics and Genomics, vol. 42, Apr. 18, 2015, pp. 301-309, 9 pages.
[cited by applicant]
Bauer, et al., “An Erythroid Enhancer of BCL11A Subject to Genetic Variation Determines Fetal Hemoglobin Level,” Science, vol. 342, Oct. 11, 2013, pp. 253-257, 4 pages.
[cited by applicant]
Beerli, et al. “Positive and negative regulation of endogenous genes by designed transcription factors” PNAS, vol. 97, Feb. 15, 2000, pp. 1495-1500.
[cited by applicant]
Beerli, et al., “Toward controlling gene expression at will: Specific regulation of the erbB-2/HER-2 promoter by using polydactyl zinc finger proteins constructed from modular building blocks”, Proc. Natl. Acad. Sci., v…
[cited by applicant]
Beerli, R., et al., “Engineering polydactyl zinc-finger transcription factors,” Nature Biotechnology, vol. 20, Feb. 2002, pp. 135-141.
[cited by applicant]
Bennett, et al., “Stable transgene expression in rod photoreceptors after recombinant adeno-associated virus-mediated gene transfer to monkey retina”, Proc. Natl. Acad. Sci., vol. 96, Aug. 1999, pp. 9920-9925.
[cited by applicant]
Bergemann, et al., Excision of specific DNA-sequences from integrated retroviral vectors via site-specific recombination:, Nucleic Acids Res., vol. 23, Oct. 2, 1995, pp. 4451-4456.
[cited by applicant]
Berns, K., et al., “A Large-Scale RNAi Screen in Human Cells Identifies New Components of the p53 Pathway,” Nature, vol. 428, Mar. 25, 2004, pp. 431-437.
[cited by applicant]
Bhaya, D., et al., “CRISPR-Cas Systems in Bacteria and Archaea: Versatile Small RNAs for Adaptive Defense and Regulation,” Annual Review of Genetics, vol. 45, 2011, pp. 273-297, (27 pages).
[cited by applicant]
Bikard, et al. “CRISPR Interference Can Prevent Natural Transformation And Virulence Acquisition During In Vivo Bacterial Infection,” Cell Host & Microbe, vol. 12, 2012, pp. 177-186.
[cited by applicant]
Bikard, et al., Supplementary Information for: “CRISPR Interference Can Prevent Natural Transformation And Virulence Acquisition During In Vivo Bacterial Infection,” Cell Host & Microbe, vol. 12, 2012, pp. 177-186.
[cited by applicant]
Birch, et al., “Plant Transformation: Problems and Strategies for Practical Application”, Annu. Rev. Plant Physiol. Plant Mol. Biol., vol. 48, 1997, pp. 297-326.
[cited by applicant]
Bloom, et al., “Inactivation of hepatitis B virus replication in cultured cells and in vivo with engineered transcription activator-like effector nucleases”, Molecular Therapy, vol. 21, Oct. 2013, pp. 1889-1897.
[cited by applicant]
Bobis-Wozowicz, S., et al., “Targeted genome editing in pluripotent stem cells using zinc-finger nucleases,” Methods, vol. 53, 2012, pp. 339-346.
[cited by applicant]
Boch, et al., “Breaking the Code of DNA Binding Specificity of TAL-Type III Effectors,” Science, vol. 326, Dec. 11, 2009, pp. 1509-1512.
[cited by applicant]
Boch, et al., “Xanthomonas AvrBs3 Family-Type III Effectors: Discovery And Function”, Annu. Rev. Phytopathol, vol. 48, 2010, pp. 419-436 (21 pages).
[cited by applicant]
Boden, et al., “Efficient Gene Transfer of HIV-1-Specific Short Hairpin RNA into Human Lymphocytic Cells Using Recombinant Adeno-associated Virus Vectors”, Molecular Therapy, vol. 9, 2004, pp. 396-402.
[cited by applicant]
Bogdanove, et al., “TAL Effectors: Customizable Proteins for DNA Targeting”, Science, vol. 333, 2011, pp. 1843-1846.
[cited by applicant]
Bohm et al., “The computer program Ludi: A new method for the de novo design of enzyme inhibitors”, Journal of Computer-Aided Molecular Design, vol. 6, 1992, pp. 61-78.
[cited by applicant]
Botta, S. et al., “Transcriptional Repression with Zinc-Finger and Tale Protein Scaffold”, Molecular Therapy, 2013, Supplement 1, p. S208, Abstract No. 539.
[cited by applicant]
Bouard, et al., “Themed Section: Vector Design and Drug Delivery Review, Viral vectors: from virology to transgene expression”, British Journal of Pharmacology, vol. 157, 2009, pp. 153-165.
[cited by applicant]
Boutros, et al., “Genome-wide RNAi analysis of growth and viability in
[cited by applicant]
Branden, C., and Tooze, J., “Prediction, Engineering, and Design of Protein Structures: Introduction to Protein Structure,” Garland Publishing, Inc., Chapter 16, 1991, p. 247.
[cited by applicant]
Briner, et al., “Guide RNA Functional Modules Direct Cas9 Activity and Orthogonality”, Molecular Cell, vol. 56, 2014, pp. 333-339.
[cited by applicant]
Brouns, S., “A Swiss Army Knife of Immunity,” Science, vol. 337, 2012, pp. 808-809.
[cited by applicant]
Brouns, S., et al., “Small CRISPR RNAs Guide Antiviral Defense in Prokaryotes,” Science, vol. 321, Aug. 15, 2008, pp. 960-964.
[cited by applicant]
Brummelkamp TR et al., “A system for stable expression of short interfering RNAs in mammalian cells,” Science, vol. 296, Apr. 19, 2002, pp. 550-553.
[cited by applicant]
C. Cayrol et al., “The THAP-zinc finger protein THAP1 regulates endothelial cell proliferation through modulation of pRB/E2F cell-cycle target genes,” Blood, vol. 109, 2007, pp. 584-594.
[cited by applicant]
C. Trapnell et al., “Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks,” Nature protocols, vol. 7, 2012, p. 562.
[cited by applicant]
C. Trapnell et al., “TopHat: discovering splice junctions with RNA-Seq.,” Bioinformatics, vol. 25, 2009, pp. 1105-1111.
[cited by applicant]
C.J, Echeverri et al., “Minimizing the risk of reporting false positives in large-scale RNAi screens,” Nature methods, vol. 3, Oct. 2006, p. 777.
[cited by applicant]
C.M Johannessen et al., “COT drives resistance to RAF inhibition through MAP kinase pathway reactivation,” Nature, vol. 468, Dec. 16, 2010, p. 968.
[cited by applicant]
C.M. Johnston et al., “Large-scale population study of human cell lines indicate that dosage compensation is virtually complete,” PLoS Genet., vol. 4, Jan. 2008, pp. 88-98, 11 pages.
[cited by applicant]
Campeau, et al., “A Versatile Viral System for Expression and Depletion of Proteins in Mammalian Cells”, PLoS One, vol. 4, 2009, pp. 1-17.
[cited by applicant]
Canver, et al., “BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis,” Nature, vol. 527, 2015, pp. 192-197, including Supplementary Material.
[cited by applicant]
Carr, et al., “Genome Engineering”, Nature Biotechnology, vol. 27, No. 12, Dec. 2009, pp. 1151-1162.
[cited by applicant]
Carroll, D., “A CRISPR Approach to Gene Targeting,” Molecular Therapy, vol. 20, 2012, pp. 1658-1660.
[cited by applicant]
Carroll., “Genome Engineering With Zing-Finger Nucleases”, Genetics, vol. 188, 2011, pp. 773-782.
[cited by applicant]
Carroll., “Progress and prospects: Zinc-finger nucleases as gene therapy agents”, Gene Therapy, vol. 15, 2008, pp. 1463-1468.
[cited by applicant]
Carte, J., et al., “Cas6 is an endoribonuclease that generates guide RNAs for invader defense in prokaryotes,” Genes Dev., vol. 22, 2008, pp. 3489-3496.
[cited by applicant]
Cermak, T., et al., “Efficient Design and Assembly of Custom TALEN and Other TAL Effector-Based Constructs For DNA Targeting,” Nucleic Acids Research, vol. 39, No. 12, Apr. 14, 2011, pp. 1-11.
[cited by applicant]
Chadderton, N., et al., “Improved Retinal Function in a Mouse Model of Dominant Retinitis Pigmentosa Following AAV-delivered Gene Therapy”, Molecular Therapy, vol. 17, Apr. 2009, pp. 593-599.
[cited by applicant]
Chan, et al. “Characterization of the Kinetochore Binding Domain of CENP-E Reveals Interactions with the Kinetochore Proteins CENP-F and hBuBR1”, The Journal of Cell Biology, vol. 143, 1998, pp. 49-63.
[cited by applicant]
Chan, Wai-Ting, et al., “Toxin-Antitoxin Genes of the Gram-Positive Pathogen
[cited by applicant]
Chang, N., et al. “Genome editing with RNA-guided Cas9 nuclease in Zebrafish embryos”, Cell Research, vol. 23, 2013, pp. 465-472.
[cited by applicant]
Chen, B., et al., “Dynamic Imaging of Genomic Loci in Living Human Cells by an Optimized CRISPR/Cas System,” Cell, vol. 155, 2013, pp. 1479-1491.
[cited by applicant]
Chen, Fuqiang, et al., “High-frequency genome editing using ssDNA oligonucleotides with zinc-finger nucleases”. Nature Methods, 2011, vol. 8, pp. 753-755, including Supplemental Online Methods.
[cited by applicant]
Chen, Jieliang, et al., “An Efficient Antiviral Strategy for Targeting Hepatitis B Virus Genome Using Transcription Activator-Like Effector Nucleases”, Molecular Therapy, vol. 22, 2014, pp. 303-311.
[cited by applicant]
Chen, S., et al., “Genome-wide CRISPR Screen in a Mouse Model of Tumor Growth and Metastasis”, Cell, vol. 160, 2015, pp. 1-15, http://dx.doi.org/10.1016/j.cell.2015.02.038.
[cited by applicant]
Chevalier et al., “Homing endonuclease: structural and functional insight into the catalysts of intron/intein mobility,” Oxford University Press., vol. 29, 2001, pp. 3757-3774.
[cited by applicant]
Chinnasamy, D., et al., “Multicistronic lentiviral vectors containing the Fmcv 2A Cleavage factor demonstrate robust expression of encoded genes at limiting MOI,” Virology Journal, vol. 3, 2006, pp. 1-16.
[cited by applicant]
Chiu, et al., “Engineered GFP as a vital reporter in plants”, Current Biology, vol. 6, 1996, pp. 325-330.
[cited by applicant]
Cho, A., et al., “Generation of Transgenic Mice,” Current Protocols in Cell Biology, Chapter Unit 19.11, 2009, pp. 1-29.
[cited by applicant]
Cho, Minseon, et al., “Quantitative selection and parallel characterization of aptamers,” PNAS, vol. 110, Nov. 12, 2013, pp. 18460-18465.
[cited by applicant]
Cho, Seung Woo, et al. “Analysis off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases” Genome Research, vol. 24, 2014, pp. 132-141.
[cited by applicant]
Cho, Seung Woo, et al., “Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease,” Nature Biotechnology, vol. 31 pp. 230-232, including Supplementary Information, 14 pages.
[cited by applicant]
Chou, JY, and Mansfield, BC., “Recombinant AAV-directed gene therapy for type I glycogen storage diseases,” Expert Opinion on Biological Therapy, vol. 11, Aug. 2011, pp. 1011-1024.
[cited by applicant]
Choulika, et al., “Transfer of Single Gene-Containing Long Terminal Repeats into the Genome of Mammalian Cells by a Retroviral Vector Carrying the cre Gene and the loxP site”, Journal of Virology, vol. 70, 1996, pp. 179…
[cited by applicant]
Christian, et al., “Supporting Information-Targeting DNA Double-Strand Breaks With TAL Effector Nucleases”, Genetics, 2010, pp. 1-8, DOI: 10.1534/110.120717:1SI-8SI.
[cited by applicant]
Christian, et al., “Targeting DNA Double-Strand Breaks With TAL Effector Nucleases”, Genetics, vol. 186, Oct. 2010, pp. 757-761.
[cited by applicant]
Chylinski, et al., “Classification and evolution of type II CRISPR-Cas systems”, Nucleic Acids Research, vol. 42, 2014, pp. 6091-6105, doi: 10.1093Inarlgku241.
[cited by applicant]
Chylinski, K., et al., “The tracrRNA and Cas9 Families of Type II CRISPR-Cas Immunity Systems,” RNA Biology, vol. 10, 2013, pp. 726-737.
[cited by applicant]
Clark, K., et al., “A Tale of Two Nucleases: Gene Targeting for the Masses?” Zebrafish, vol. 8, No. 3, 2011, pp. 147-149.
[cited by applicant]
Cockrell, “Berkeley's Wikipedian-in-residence is a first,” NewsCenter, Feb. 25, 2014, downloaded from https://newscenter.berkeley.edu/2014/02/25/berkeleys-wikipedian-in-residence-is-a-first/, May 8, 2015, 3 pages.
[cited by applicant]
Community Corner, “CRISPR technology for gene therapy,” Nature Medicine, vol. 20, May 2014, pp. 476-477.
[cited by applicant]
Cong, et al., Oct. 5, 2012 Manuscript including Supplementary Materials, “CRISPR-Assisted Mammalian Genome Engineering,” published as “Multiplex Genome Engineering Using CRISPR-Cas Systems,” Science, vol. 339, 2013, pp.…
[cited by applicant]
Cong, L., et al., “Comprehensive interrogation of natural TALE DNA-binding modules and transcriptional repressor domains,” Nature Communications, vol. 3, Jul. 24, 2012, pp. 968-973.
[cited by applicant]
Cong, L., et al., “In Vivo Genome Engineering With AAV Vector Carrying CRISPR-Cas9 System,” Molecular Therapy, vol. 22, May 2014, Supplement 1, p. S214.
[cited by applicant]
Cong, L., et al., “Multiplex Genome Engineering Using CRISPR-Cas Systems,” Science, vol. 339, 2013, pp. 819-823.
[cited by applicant]
Cong, L., et al., Supplementary Material for: “Multiplex Genome Engineering Using CRISPR-Cas Systems,” Science, vol. 339, 2013, pp. 819-823.
[cited by applicant]
Connor, S., “Scientific split—the human genome breakthrough dividing former colleagues,” The Independent, http://www.independent.co.uk/news/science/scientific-split--the-human-genome-breakthrough-dividing-former-colleag…
[cited by applicant]
Costantino, et al., “Enhanced levels of alpha Red-mediated recombinants in mismatch repair mutants”, PNAS, vol. 100, 2003, pp. 15748-15753.
[cited by applicant]
Cotropia, et al., “Copying in Patent Law,” N.C.L. Rev., Stanford Public Law Working Paper No. 1270160, 2009, pp. 1-46.
[cited by applicant]
Cummings et al., “Fourteen and counting: unraveling trinucleotide repeat diseases”, Human Molecular Genetics, vol. 9, 2000, pp. 909-916.
[cited by applicant]
D.J.Burgess et al., “Topoisomerase levels determine chemotherapy response in vitro and in vivo,” Proceedings of the National Academy of Sciences, vol. 105, Jul. 1, 2008, pp. 9053-9058.
[cited by applicant]
Daboussi, F., et al., “Chromosomal context and epigenetic mechanisms control the efficacy of genome editing by rare-cutting designer endonucleases,” Nucleic Acids Research, vol. 40, 2012, pp. 6367-6379.
[cited by applicant]
Dahlman, J., et al., “In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight,” Nature Nanotechnology, vol. 9, 2014, pp. 648-655.
[cited by applicant]
Dai, et al. “Genes:Structures and Regulation: The Transcription Factors GATA4 and dHAND Physically Interact to Synergistically Activate Cardiac Gene Expression through a p300-dependent Mechanism”, J. Biol. Chem., vol. 2…
[cited by applicant]
Daley, J., and Wilson, T., “Rejoining of DNA Double-Strand Breaks as a Function of Overhang Length,” Molecular and Cellular Biology, vol. 25, 2005, pp. 896-906.
[cited by applicant]
Damian, M., and Porteus, M., “A Crisper Look at Genome Editing: RNA-guided Genome Modification,” Molecular Therapy, vol. 21, Apr. 2013, pp. 720-722.
[cited by applicant]
Database GenBank, “
[cited by applicant]
Database GenBank: “CRISPR-associated protein, Csn1 family,
[cited by applicant]
Database UniProt: “CRISPR-associated endonuclease Cas9:
[cited by applicant]
Database UniProtKB/TrEMBL [online], Accession No. QOP897, “The genome sequence of the food-borne pathogen Campylobacter jejuni reveals hypervariable sequences,” Subname: Full=Putative CRISPR-associated protein, Oct. 3, …
[cited by applicant]
Database UniProtKB/TrEMBL, Accession No. D0W2Z9, http://www.uniprot.org/uniprot/D0W2Z9.txt?version=4, dated Oct. 3, 2012, 1 page.
[cited by applicant]
Database UniProtKB/TrEMBL, Accession No. G1UFN3, http://www.uniprot.org/uniprot/G1UFN3.txt?version=3, dated Oct. 3, 2012, 1 page.
[cited by applicant]
Database UniProtKB/TrEMBL, Accession No. J3TRJ9, http://www.uniprot.org/uniprot/J3TRJ9.txt?version=2, dated Oct. 31, 2012, 1 page.
[cited by applicant]
Database UniProtKB/TrEMBL, Accession No. Q6NK13, http://www.uniprot.org/uniprot/Q6NKI3.txt?version=43, dated Jun. 13, 2012, 1 page.
[cited by applicant]
Database UniProtKB/TrEMBL, Accession No. Q73QW6, http://www.uniprot.org/uniprot/Q73QW6.txt?version=4, dated Nov. 28, 2012, 2 pages.
[cited by applicant]
Database WPI, Week 201437 Thomson Scientific, London, GB; AN 2014-J79552, XP-002737563, 2 pages.
[cited by applicant]
Datsenko, et al. “Molecular memory of prior infections activates the CRISPR/Cas adaptive bacterial immunity system”, Nature Communications, vol. 3, 2012, pp. 1-7.
[cited by applicant]
Dean., “Recent Advances in Drug Design Methods: Where Will They Lead?”, BioEssays, vol. 16, Sep. 1994, pp. 683-687.
[cited by applicant]
Decision on Motions—PTAB, The Regents of the University of California v. The Broad Institute, Inc., filed Sep. 10, 2020, in Patent Interference No. 106,115 (DK), 113 pages.
[cited by applicant]
Declaration of Feng Zhang for U.S. Appl. No. 14/054,414 dated Jan. 30, 2014 (10 pages).
[cited by applicant]
Declaration of Technical Expert Paul Simons dated Dec. 22, 2015, 76 pages.
[cited by applicant]
Deltcheva, E., et al., “CRISPR RNA Maturation by Trans-Encoded Small RNA and Host Factor RNase III,” Nature, vol. 471, Mar. 31, 2011, pp. 602-609.
[cited by applicant]
Deltcheva, et al., “Supplementary Information: CRISPR RNA Maturation By Trans-Encoded Small RNA and Host Factor RNase III” Nature, pp. 1-35.
[cited by applicant]
Deveau, H et al., “Phage Response to CRISPR-Encoded Resistance in
[cited by applicant]
Deveau, H., et al., “CRISPR/Cas System and Its Role in Phage-Bacteria Interactions,” The Annual Review of Microbiology, vol. 64, 2010, pp. 475-493.
[cited by applicant]
Dicarlo, et al., “Genome engineering in
[cited by applicant]
Dingwall, et al. “A Polypeptide Domain That Specifies Migration Of Nucleoplasmin into The Nucleus”, Cell, vol. 30, 1982, pp. 449-458, (Abstract only).
[cited by applicant]
Dingwall, et al., “The Nucleoplasmin Nuclear Location Sequence Is Larger and More Complex than That of SV-40 Large T Antigen”, The Journal of Cell Biology, vol. 107, 1988, pp. 841-849.
[cited by applicant]
Do, et al., “Identification of multiple nuclear localization signals in murine Elf3, an ETS transcription factor” FEBS Letters, vol. 580, 2006, pp. 1865-1871.
[cited by applicant]
Doench, et al., “Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation,” Nature Biotechnology, vol. 32, 2014, pp. 1262-1267, including Supplementary Material, 17 pages.
[cited by applicant]
Dominguez, et al., “Beyond editing: repurposing CRISPR-Cas 9 for precision genome regulation and interrogation” Nat Rev Mol Cell Biol., vol. 17, 2016, 17 pp. 5-15.
[cited by applicant]
Dong, et al., “The crystal structure of Cpf1 in complex with CRISPR RNA,” Nature, vol. 532, 2016, pp. 523-525.
[cited by applicant]